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ABSTRACT: The prothrombinase complex catalyzes the activation of prothrombin to R-thrombin. We
have repetitively shown that amino acid region 695DYDY698 from the COOH terminus of the heavy
chain of factor Va regulates the rate of cleavage of prothrombin at Arg271 by prothrombinase. We
have also recently demonstrated that amino acid region 334DY335 is required for the optimal activity
of prothrombinase. To assess the effect of these six amino acid residues on cofactor activity, we
created recombinant factor Va molecules combining mutations at amino acid regions 334–335 and
695-698 as follows: factor V3K (334DY335 f KF and 695DYDY698 f KFKF), factor VKF/4A (334DY335
f KF and 695DYDY698 f AAAA), and factor V6A (334DY335 f AA and 695DYDY698 f AAAA). The
recombinant factor V molecules were expressed and puriﬁed to homogeneity. Factor Va3K, factor
VaK4/4A, and factor Va6A had reduced afﬁnity for factor Xa, when compared to the afﬁnity of the
wild-type molecule (factor VaWt) for the enzyme. Prothrombinase assembled with saturating
concentrations of factor Va3K had a 6-fold reduced second-order rate constant for prothrombin activation
compared to the value obtained with prothrombinase assembled with factor VaWt, while prothrombinase
assembled with saturating concentrations of factor VaKF/4A and factor Va6A had approximately 1.5-
fold reduced second-order rate constants. Overall, the data demonstrate that amino acid region 334–335
together with amino acid region 695-698 from factor Va heavy chain are part of a cooperative
mechanism within prothrombinase regulating cleavage and activation of prothrombin by factor Xa.
R-Thrombin is required for survival and is formed fol-
lowing activation of its inactive precursor, prothrombin, by
the prothrombinase complex (1). The prothrombinase com-
plex is composed of the enzyme, factor Xa, and the protein
cofactor, factor Va, assembled on a membrane surface in
the presence of divalent metal ions (1, 2). Even though factor
Xa alone can activate prothrombin, the rate of this reaction
is not compatible with survival. Incorporation of factor Va
into the prothrombinase complex increases the catalytic
efﬁciency of prothrombin activation by 5 orders of magni-
tude, thus providing the physiological pathway for R-throm-
bin production. This increase in the efﬁciency of prothrom-
binase is the result of a 100-fold decrease in the Km and a
3000-fold increase in the kcat of prothrombinase compared
to those for factor Xa alone. The decrease in the Km is the
result of a tighter interaction of the prothrombinase complex
with the membrane surface, which results in higher local
concentrations of the enzyme, while the increase in the kcat
of the enzyme is credited solely to the productive interaction
between factor Va and factor Xa (3-5). While the exact
molecular mechanism by which factor Va exerts its cofactor
function is still under investigation, it has been well
established that the productive interaction of the heavy chain
of factor Va with prothrombin involves anion binding exosite
I of prothrombin (6-11). Human factor V circulates in
plasma as a single-chain inactive precursor. Proteolytic
cleavage of the procofactor by R-thrombin at Arg709, Arg1018,
and Arg1545 produces a heterodimer consisting of a heavy
chain (Mr ∼ 105000; A1 and A2 domains) and a light chain
(Mr ∼ 74000; A3, C1, and C2 domains) associated through
divalent metal ions (12-15) (Figure 1). We have demon-
strated that a binding site for factor Xa is contained within
the heavy chain of the cofactor (16, 17), and we have
established that the COOH terminus of the factor Va heavy
chain (amino acids 680-709) is essential for optimal
expression of cofactor activity because it promotes a produc-
tive interaction with prothrombin, regulating the rate of
cleavage at Arg271 by prothrombinase (18-21). This region
of the cofactor is highly acidic in nature and contains several
tyrosine residues that have been shown to have potential to
be involved in factor V activation by R-thrombin and proper
cofactor function (22). We have also recently shown that
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Va (amino acid region 334–335) are crucial for cofactor
function (23). This study was undertaken to understand the
importance of these two spatially distinct, important regions
of factor Va heavy chain when acting in concert on
prothrombinase complex assembly and function.
EXPERIMENTAL PROCEDURES
Materials and Reagents. Diisopropyl ﬂuorophosphate (DFP),
O-phenylenediamine (OPD) dihydrochloride, N-(2-hydroxy-
ethyl)piperazine-N′-2-ethanesulfonic acid (Hepes), Trizma (Tris
base), and Coomassie Brilliant Blue R-250 were purchased from
Sigma (St. Louis, MO). Factor V-deﬁcient plasma was from
Research Protein Inc. (Essex Junction, VT). Secondary anti-
mouse and anti-sheep IgG coupled to peroxidase were pur-
chased from Southern Biotechnology Associates Inc. (Birming-
ham, AL). L-R-Phosphatidylserine (PS)
1 and L-R-
phosphatidylcholine (PC) were from Avanti Polar Lipids
(Alabaster, AL). Chemiluminescent reagent ECL+ and Heparin-
Sepharose were from AmershamPharmacia Biotech Inc. (Pis-
cataway, NJ). Normal reference plasma and chromogenic
substrate Spectrozyme-TH were from American Diagnostica
Inc. (Greenwich, CT). RecombiPlasTin for the clotting assays
was purchased from Instrumentation Laboratory Co. (Lexington,
MA). Dansylarginine-N-(3-ethyl-1,5-pentanediyl) amide (DAPA),
human factor Xa, human R-thrombin, and human prothrombin
were purchased from Haematologic Technologies Inc. (Essex
Junction, VT). Factor V cDNA was from American Type Tissue
Collection (Manassas, VA) (ATCC catalog no. 40515 pMT2-
V). All restriction enzymes were from New England Biolabs
(Beverly, MA). All molecular biology and tissue culture
reagents, speciﬁc primers, and medium were from Gibco,
Invitrogen Corp. (Grand Island, NY), or as indicated. Human
factor V monoclonal antibodies (RHFVHC17 and RHFVLC9) and
monoclonal antibody RHFV1 coupled to Sepharose were
provided by K. G. Mann (Department of Biochemistry,
University of Vermont, Burlington, VT).
Construction of Recombinant Factor V Molecules. Factor
VKFKF and factor V4A were constructed as previously
described by our laboratory (19, 21). Recombinant factor V
molecules with combining mutations, factor V3K, factor
VKF/4A, and factor V6A, were constructed using Stratagene’s
QuikChange XL site-directed mutagenesis kit. Factor V3K
was constructed using the mutagenic primers 5′-C ATT TGG
AAGTTT GCA CCT G-3′ (forward) and 5′-C AGG TGC
AAA CTTCCA AAT G-3′ (reverse) (corresponding to
334DY335 f KF mutations), using factor VKFKF as a template
(bold underlined letters identify the mutated bases) (19). To
construct factor VKF/4A, these same primers were used and
factor V4A (21) was used as the template in the PCR. Factor
V6A was constructed with the primers 5′-GAG GAA GTC
ATT TGG GCC GCC GCA CCT GTA ATA-3′ (forward)
and 5′-TAT TAC AGG TGC GGC GGC CCA AAT GAC
TTC CTC-3′ (reverse), with factor V4A (21) as the template
in the PCR. The mutations were conﬁrmed by DNA
sequencing (DNA Analysis Facility, Cleveland State Uni-
versity).
Transient Transfection, Puriﬁcation, and Assay of Recom-
binant Factor V Molecules. Puriﬁed wild-type factor V
(factor VWt), factor V3K, factor VKF/4A, and factor V6A
plasmids were transfected into the COS-7L cells with fugene
6 (Roche Diagnostics), according to the manufacturer’s
instructions as described extensively by our laboratory (17, 24).
The recombinant proteins were puriﬁed ona2m Lcolumn
of monoclonal antibody RhFV1 coupled to Sepharose as
described previously (25). The puriﬁed proteins were stored
at -80 °C in small aliquots to avoid repeated freeze-thaw
cycles. The activity and the integrity of the recombinant
factor V molecules were conﬁrmed by clotting assays using
factor V-deﬁcient plasma and Western blotting with mono-
clonalandpolyclonalantibodiesasdescribedpreviously(26,27).
Following activation of factor V, R-thrombin was inhibited
by the addition of DFP. It is also important to note that any
residual R-thrombin activity that could contribute to our
experimental data is eliminated by the addition of DAPA to
the reaction mixtures. DAPA is a very potent synthetic
inhibitor of R-thrombin and eliminates any feedback activity
that would interfere in experiments presented herein. A
detailed description of all details relating to our experimental
procedures is provided in refs 17, 24, 25, and 28.
Gel Electrophoresis and Western Blotting. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
analyses were carried out using 4 to 12% gradient gels or
1 Abbreviations: PS, L-R-phosphatidylserine; PC, L-R-phosphatidyl-
choline; PCPS, small unilamellar phospholipid vesicles composed of
75%PCand25%PS(w/w);SDS-PAGE,sodiumdodecylsulfate-polyacryl-
amide gel electrophoresis; PVDF, polyvinylidene diﬂuoride; factor VaWt,
recombinant human wild-type factor Va; factor VaKF, recombinant
human factor Va with the D334 f K and Y335 f F mutations; factor
VaAA, recombinant human factor Va with the D334 f A and Y335 f A
mutations; factor VKFKF, recombinant human factor V with the
695DYDY698 f KFKF mutation; factor V4A, recombinant human factor
V with the 695DYDY698 f AAAA mutation; factor Va3K, recombinant
human factor Va with the D334 f K, Y335 f F, D695 f K, Y696 f F,
D697 f K, and Y698 f F mutations; factor Va6A, recombinant human
factor Va with the D334 f A, Y335 f A, D695 f A, Y696 f A, D697 f
A, and Y698 f A mutations; factor VKF/4A, recombinant human factor
Va with the D334 f K, Y335 f F, D695 f A, Y696 f A, D697 f A, and
Y698 f A mutations.
FIGURE 1: Human factor V structure. Factor V is composed of 2196
amino acids with three A domains, a connecting B region, and two
C domains. The procofactor is activated following three cleavages
by R-thrombin at Arg709, Arg1018, and Arg1545. The mutations within
a 13-amino acid region of the A2 domain of the heavy chain of
the molecule that is crucial for cofactor activity (amino acid residues
323-335) (23) and within the acidic hirudin-like COOH-terminal
region of the heavy chain (amino acid residues 680-709) required
for the optimal function of prothrombinase (20, 21) are indicated
together with the designation of the recombinant mutant factor V
molecules created and used throughout this work. Residues DY
from both regions that are mutated in this study are bold and
underlined.
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according to the method of Laemmli, and the protein was
visualized by being stained with Coomassie Brilliant Blue
R-250, followed by destaining in a solution of methanol,
acetic acid, and water (29). In several experiments, the
protein was transferred to polyvinylidene diﬂuoride (PVDF)
membranes following the method described by Towbin et
al. (30). Factor Va heavy and light chains were probed with
the appropriate monoclonal and polyclonal antibodies and
visualized with chemiluminescence.
Kinetic Titrations of Prothrombinase. The ability of the
recombinant factor V molecules to assemble in the pro-
thrombinase complex and bind to the enzyme was assessed
in a discontinuous assay described in detail elsewhere (24).
All recombinant factor V molecules were activated with
R-thrombin, and reaction mixtures contained PCPS vesicles
(20 µM), DAPA (3 µM), and factor Xa (varying concentra-
tions), in reaction buffer consisting of HEPES, 0.15 M NaCl,
5 mM CaCl2, and 0.01% Tween 20 (pH 7.40). For the
practical calculation of the KD between the factor Va
molecules and factor Xa, assays were performed in the
presence of a limiting factor Xa concentration (15 pM) and
varying concentrations of the recombinant factor Va species
(25 pM to 5 nM). For the determination of the kinetic
constants of prothrombinase function (Km and kcat), experi-
ments were conducted with a limiting amount of factor Xa
(5 pM) in the presence of a ﬁxed saturating amount of the
various recombinant factor Va molecules (10-30 nM) and
varying the substrate concentration. The rate of R-thrombin
generation was measured using a chromogenic substrate,
Spectrozyme TH, which probes for R-thrombin generation.
The initial rate of R-thrombin generation was analyzed with
Prizm (GraphPad). The change in transition-state stabilization
free energy, which measures the effect of the mutations in
the cofactor on the catalytic site of the enzyme, was
calculated for the double mutants as extensively described
previously by our laboratory (23, 24).
Studies of the Pathway for Prothrombin ActiVation by Gel
Electrophoresis. Prothrombin was incubated in a reaction
mixture containing 20 µM PCPS, 50 µM DAPA, and various
concentrations of factor VaWt, factor Va3K, factor VaKF/4A,
and factor Va6A (activated with R-thrombin, 10-30 nM) in
TBS with Ca2+. A zero point was taken, and the addition of
factor Xa (1 nM) marked the start of the reaction. Aliquots
of the reaction mixture were removed at selected time points
and treated as described previously (20, 24). Calculations
of the rates of prothrombin consumption were performed as
described (20).
Molecular Dynamics Simulations. The amino acid changes
in the factor Va model (15) were introduced using SwissP-
dbViewer. Amino acid side chain orientation was selected
using the rotamer library provided with SwissPdbViewer
(31). The new model [factor Va3K (D334 f K, Y335 f F,
D695 f K, Y696 f F, D697 f K, Y698 f F)] was solvated in
a simulation box using the SPC water model using the
GROMACS package (32). The minimum distance between
the periodic images of the molecule was set to 1 nm. The
simulation time was set to 3 ns. Simulation details were kept
the same as recently described for the study of factor Va
molecules with mutations in the D334-Y335 region (23). The
simulation equilibrated after 2 ns, and the last nanosecond
was used for analysis. Equilibration of the system was also
assessed on the basis of the negligible drift of several
parameters such as the potential energy, pressure, and
temperature.
RESULTS
Transient Expression and ActiVation of Recombinant
Factor V Molecules. To assess the importance of amino acid
regions 334–335 and 695-698 from the heavy chain of factor
Va, we constructed molecules that combine mutations in
these previously identiﬁed “hot spots” of the molecule
(21, 23) (Figure 1). We prepared recombinant factor Va
molecules, factor V3K (D334K, Y334F, D695K, Y696F,
D697K, and Y698F), factor VKF/4A (D334K, Y335F, D695A,
Y696A, D697A, and Y698A), and factor V6A (D334A,
Y335A, D695A, Y696A, D697A, and D698A) (Figure 1).
Recombinant factor VWt and the mutant molecules were
expressed in mammalian cells and puriﬁed to homogeneity
as described previously (25). Figure 2 illustrates a typical
quality control procedure highlighting factor V3K. Following
activation by R-thrombin, SDS-PAGE analyses followed
by immunoblotting with speciﬁc monoclonal antibodies to
the heavy and light chain of the cofactor demonstrate that
the mutant recombinant protein is intact, homogeneous, and
composed of heavy and light chains that migrated according
to their expected molecular weights (Figure 2A). In addition,
control experiments using a polyclonal antibody to factor V
demonstrate that all factor V molecules were fully activated
prior to use (Figure 2B). Similar results were obtained with
factor VKF/4A and factor V6A.
The recombinant molecules were ﬁrst assessed for their
clotting activity in a two-stage assay. R-Thrombin activation
of factor VWt resulted in a cofactor with clotting activity
(2400 units/mg) similar to that of the plasma-derived
molecule (2500 units/mg). Under similar experimental condi-
tions, all mutant recombinant factor Va molecules displayed
FIGURE 2: Electrophoretic analyses of wild-type factor V and
recombinant factor V3K. (A) Factor VWt and factor V3K were
activated with R-thrombin as described in Experimental Procedures
and analyzed by SDS-PAGE. Following transfer to a PVDF
membrane, immunoreactive fragments were detected with mono-
clonal antibodies RHFVaHC17 (recognizing an epitope on the heavy
chain of the cofactor between amino acid residues 307 and 506)
and RHFVaHC9 (recognizing the light chain). (B) Factor VWt and
factor V3K were activated with R-thrombin and analyzed by
SDS-PAGE. Following transfer to a PVDF membrane, immu-
noreactive fragments were detected with a polyclonal antibody. In
both cases, the immunoblot containing the mutant molecule was
overexposed. At the right are shown the positions of the heavy
and light chains of factor Va.
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molecule. Factor Va6A had a 4-fold decrease in clotting
activity (600 units/mg); factor VaKF/4A displayed a 6.3-fold
reduction in clotting activity (380 units/mg), while factor
Va3K was most impaired in its clotting activity with a 20-
fold decrease (120 units/mg). These data demonstrate that
the mutations are detrimental to factor Va clotting activity.
Kinetic Analyses of Recombinant Factor Va Molecules.
We examined the ability of the recombinant factor Va
molecules to bind factor Xa and assemble in prothrombinase
using an assay employing puriﬁed reagents and a chromoge-
nic substrate to probe for R-thrombin generation. The assay
was performed under conditions of limiting factor Xa
concentrations while the concentration of recombinant factor
Va molecules was varied. Figure 3 and Table 1 show the
results of the kinetic studies. The data demonstrate that under
the experimental conditions that were used, factor VaWt has
an afﬁnity for the enzyme, factor Xa, similar to that of its
plasma counterpart (Table 1). Conversely, the recombinant
factor Va molecules, factor Va3K, factor VaKF/4A, and factor
Va6A, were impaired in their ability to bind the enzyme,
having dissociation constants ∼6-8-fold higher than that of
the wild-type molecule. These results are surprising because
when amino acid regions 334–335 and 695-698 are mutated
separately, there is no signiﬁcant effect on the dissociation
constant of the recombinant molecules for plasma-derived
factor Xa (Table 1) (21, 23). These data suggest that the
mutations destabilize the factor Va binding domain(s) for
factor Xa.
We further evaluated the effect of the mutations on the
Km and kcat values of prothrombinase. The raw data are
displayed in Figure 3B, and the kinetic constants are provided
in Figure 4 and Table 1. Because we wanted to prevent the
possibility that differences between prothrombinase as-
sembled with factor VaWt and prothrombinase assembled with
the factor Va mutant molecules may be attributed to subtle
differences in the KDapp of factor Va for factor Xa, which
would result in a smaller amount of prothrombinase formed,
all experiments described below were conducted under
conditions where more than 95% of factor Xa was saturated
with factor Va. Calculations were performed using the
dissociation constants of all recombinant molecules for factor
Xa shown in Table 1. Under the experimental conditions
that were employed, the mutations had no effect on the Km
of the reaction, while the catalytic efﬁciencies of prothrom-
binase assembled with the mutant recombinant cofactor
molecules were decreased compared to the catalytic ef-
ﬁciency of prothrombinase assembled with factor VaWt
(Figure 4A). The data show that prothrombinase assembled
with factor Va3K, factor VaKF/4A, or factor Va6A had a 6-,
1.7-, or 1.3-fold reduced catalytic efﬁciency, respectively,
compared to the value obtained for prothrombinase as-
sembled with factor VaWt. Conversely, when amino acid
region of residues 695-698 alone is mutated to either KFKF
or AAAA, factor VaKFKF and factor Va4A have 1.2- and 1.4-
fold increased catalytic efﬁciencies, respectively, compared
to the wild-type molecule (Table 1 and Figure 4A). This
increased catalytic efﬁciency can be explained by sustained
meizothrombin accumulation as recently demonstrated (21).
Indeed, when the ability of the recombinant factor Va
molecules to be incorporated into prothrombinase and
activate prothrombin was investigated by gel electrophoresis,
persistence of meizothrombin was observed in the case of
prothrombin activation by prothrombinase assembled with
factor VaKFKF and factor Va4A as assessed by the lingering
of fragment 1·2-A which is indicative of initial cleavage at
Arg320 (not shown). However, prothrombinases assembled
with the cofactor molecules bearing the combined mutations
have a slower rate of prothrombin consumption compared
to the rates of prothrombin consumption by prothrombinase
assembled with factor VaWt, indicating that prothrombinase
assembled with factor Va3K, factor VaKF/4A, and factor Va6A
FIGURE 3: (A) Factor Va titrations to determine the afﬁnity of the
recombinant factor Va molecules for factor Xa. R-Thrombin
generation experiments were carried out as described in Experi-
mental Procedures. The prothrombinase complex was assembled
with varying concentrations of recombinant factor VaWt (9), factor
Va3K (2), factor VaKF/4A (1), and factor Va6A (b). The solid lines
represent a nonlinear regression ﬁt of the data using GraphPad Prizm
for a one-binding site model. Titrations were performed in triplicate
with at least three different preparations of puriﬁed proteins. (B)
Prothrombin titrations to determine the kinetic parameters of
prothrombinase assembled with various recombinant factor Va
species. R-Thrombin generation experiments were carried out as
described in Experimental Procedures by varying the substrate
concentration (from 25 nM to 4 µM) with 5 pM factor Xa saturated
with the factor Va species. The prothrombinase complex was
assembled with recombinant factor VaWt (9), factor Va3K (2), factor
VaKF/4A (1), and factor Va6A (b). The solid lines represent the
nonlinear regression ﬁt of the data using GraphPad Prizm for the
Michaelis-Menten equation. The data shown are the averages of
ﬁve different titrations with different preparations of puriﬁed
proteins.
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Arg320 and Arg271. The inability of prothrombinase assembled
with the three mutant cofactor molecules to function
optimally can be explained by the inability of factor Xa to
efﬁciently convert prothrombin to R-thrombin because of
diminished productive collisions between the enzyme and
prothrombin. Comparison of the second-order rate constant
between prothrombinase assembled with the recombinant
molecules (kcat/Km) demonstrates that the turnover number
for prothrombinase assembled with the mutant molecules is
1.7-6-fold reduced (Figure 4B). Overall, the data demon-
strate that amino acid regions 334–335 and 695-698 have
important cooperative roles during prothrombin activation
by prothrombinase.
Thermodynamic Effect of the Mutations in the HeaVy
Chain of Factor Va on Prothrombinase Function. Since
prothrombinase is an enzyme composed of a catalytic subunit
(factor Xa) and a regulatory subunit (factor Va), any
perturbation in the interaction between the two proteins or
any perturbations in the interaction of prothrombinase with
the substrate caused by a mutation in the regulatory subunit
may (will) inﬂuence the catalytic activity of factor Xa. The
kinetic data showed that the factor VaWt f factor Va3K
transition results in a dramatic decrease in the catalytic
efﬁciency of factor Va translated by a positive value for
∆∆Gq
Wtf3K of ∼1.1 kcal/mol (Scheme 1). To determine if
the side chains of the amino acids that are part of the two
separate sites on the heavy chain of factor Va under
investigation (334DY335 and 695DYDY698) interact with each
other to affect the catalytic efﬁciency of factor Xa, thermo-
dynamic cycles were created and the exchange in free energy
was calculated and is shown in Scheme 1. Factor Va3K has
a ∆∆Gint value of +0.47 kcal/mol, indicating that the DY
f KF substitutions at amino acid regions 334–335 and
695-698 indeed have an additive effect. However, the severe
detrimental effect of the 334DY335 f KF substitution in the
heavy chain for cofactor activity (23) is partially offset by
the increased catalytic activity of meizothrombin that lingers
following activation of prothrombin by prothrombinase
assembled with factor VaKFKF (Figure 4B). Similar results
were found with prothrombinase assembled with factor
VaKF/4A and factor Va6A. However, substituting all amino
acids with alanine had a less detrimental effect on factor Va
cofactor activity than when charge reversal mutations were
introduced. The data demonstrate a differential effect of the
mutations depending on both their nature and their location.
Mutations in region 334–335 alone are detrimental to the
Table 1: Functional Properties of Recombinant Factor Va Molecules
factor Va species KDapp (nM)
a Km (µM)
b kcat (s-1)
b
factor VaPlasma 0.5 ( 0.2
c 0.3 ( 0.05 40.5 ( 2
factor VaWt 0.3 ( 0.1 0.3 ( 0.04 38.4 ( 1
factor VaKFd 0.6 ( 0.2 0.4 ( 0.06 19.2 ( 0.5
factor VaAAd 0.6 ( 0.15 0.6 ( 0.07 14.4 ( 1
factor Va4A 0.4 ( 0.2
c 0.3 ( 0.06 53.4 ( 2
factor VaKFKF 0.4 ( 0.2 0.3 ( 0.04 46.7 ( 3
factor Va3K 1.8 ( 0.7 0.3 ( 0.10 6.4 ( 1
factor VaKF/4A 2.5 ( 0.8 0.5 ( 0.06 23.2 ( 1
factor Va6A 2.3 ( 0.2 0.4 ( 0.08 29.6 ( 2
a Apparent dissociation constants of recombinant factor Va for
plasma-derived factor Xa (KDapp) were determined as described in
Experimental Procedures at limiting factor Xa concentrations (the raw
data are provided in Figure 3A).
b Apparent Km and kcat were determined
as described in Experimental Procedures at limiting factor Xa
concentrations (5 pM) and saturating concentrations of factor Va (the
raw data are provided in Figure 3B).
c From ref 21.
d The recombinant
molecules were fully characterized in ref 23.
FIGURE 4: Determination of the kinetic parameters of prothrombi-
nase assembled with the various recombinant factor Va species.
R-Thrombin generation experiments were carried out as described
in Experimental Procedures by varying the substrate concentration
(see Figure 3B). The Km for all cofactor molecules is given in Table
1, while the kcat is shown in panel A (min-1). Panel B provides the
second-order rate constants (M-1 s-1).
Scheme 1: Thermodynamic Cycle for Prothrombinase
Activity following Substitutions in Factor Va Heavy Chain
a
a ∆∆Gint is the free energy of interaction between the side chains of
334DY335 and 695DYDY698 of factor Va heavy chain and was calculated
with eqs 3 and 4 of ref 23. The values illustrated on the arrows identify
the ∆∆Gq between recombinant species as indicated. Parallel arrows
show the difference in catalytic efﬁciency between prothrombinase
assembled with different mutant factor Va molecules. Different forms
of prothrombinase are compared for their ability to activate prothrombin
(∆∆Gq
WTfKF and ∆∆Gq
WTfAA taken from ref 23).
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while mutations in the COOH-terminal portion of the heavy
chain of the molecule alone are perceived as beneﬁcial since
they result in increased kcat values because of delayed
cleavage at Arg271 and persistence of meizothrombin (21).
We must thus conclude that the overall lower rate of
R-thrombin formation by prothrombinase assembled with
factor Va3K as compared to prothrombinase assembled with
factor VaWt is the direct result of decreased productive
collisions between enzyme and substrate. Thus, these six
amino acid residues from the heavy chain of factor Va
stabilize the interaction of factor Xa with the cofactor and
appear to be directly involved in the activity of prothrom-
binase because they may be also responsible for the interac-
tion with prothrombin.
Structural Consequences of the Mutations. Figure 5 was
constructed using the ﬁnal snapshot of the model taken at 3
ns. The ﬁgure shows amino acid residues D334 and Y335 as
blue sticks and amino acid residues K695-F698 as red sticks.
The R-helix structure of amino acid region S528-F538 of the
factor Va3K molecule was found to be preserved during the
simulation (Figure 5, red cartoon). The center of mass of
the R-helix from the factor Va3K molecule is shifted by 6.8
Å as compared with the same structure in the unmodiﬁed
factor Va molecule. The closest distance between the
S528-F538 R-helix and the 695-698 region was found to be
∼24 Å in the case of factor Va3K as compared to ∼3 3Åi n
the case of unmodiﬁed factor Va. Such a small distance
between these amino acid groups in the factor Va3K molecule
is probably due to the stronger electrostatic interaction
deriving from the charge reversal mutations (i.e., D f Ka t
positions 695 and 698).
DISCUSSION
Our data demonstrate that amino acid region 334–335
together with amino acid region 695-698 of factor Va heavy
chain work in concert for efﬁcient conversion of prothrombin
to R-thrombin by factor Xa within prothrombinase. We have
recently demonstrated that amino acid region D334-Y335 is
critical for optimum rearrangement of enzyme and substrate
required for efﬁcient catalysis of prothrombin by prothrom-
binase (23). Mutation of these residues results in a molecule
that is impaired in its cofactor capabilities for prothrombin
activation. We have also established that residues 695DYDY698
from the COOH terminus of factor Va heavy chain are
involved in cofactor function and regulate the rate of
meizothrombin cleavage by prothrombinase at Arg271 (20, 21).
The data presented here demonstrate that when all six
residues are mutated simultaneously, there is a signiﬁcant
effect on cofactor activity. However, depending on the nature
of amino acid substitutions and their location, the effect may
be large (nearly 6-fold reduction in the catalytic efﬁciency
of prothrombinase assembled with factor Va3K) or modest
(1.7-fold reduction in the catalytic efﬁciency of prothrom-
binase made with factor Va6A). In contrast, substitution of
the amino acids in the two regions separately results in an
8-fold activity decrease or a 1.2-fold activity increase for
prothrombinase assembled with either factor VaKF or factor
VaKFKF, respectively (ref 23 and data presented here).
Interestingly, while prothrombinase assembled with factor
VaAA is still severely impaired in its catalytic efﬁciency,
prothrombinase assembled with factor Va4A has an ∼40%
higher catalytic efﬁciency than prothrombinase assembled
with the wild-type molecule. As a consequence, a less
detrimental effect for prothrombin activation was observed
with prothrombinase assembled with factor Va6A as dem-
onstrated by our assay using a chromogenic substrate to
assess R-thrombin generation. All these ﬁndings can explain
the dramatic loss of clotting activity of the mutant cofactors
because of sustained meizothrombin generation (21). Meizo-
thrombin has poor clotting activity because it has not yet
exposed ABE-II that is covered by fragment 2 which is
released upon cleavage at Arg271 (33, 34). Overall, the results
support our early hypothesis that amino acid regions 334–335
and 695-698 are on the surface of factor Va heavy chain
and act in concert for optimal cofactor effect during
prothrombin activation (15).
We have recently reported that the distances between the
centers of masses of the CR atoms between amino acids 334
and 335 and the extremities of the factor Xa binding site
taken separately, one by one, did not signiﬁcantly change
(23). However, while distance analysis between the center
of masses of amino acid regions D695-Q699 and D334–Y335
showed an approximate distance of 16.1 Å in factor VaWt,a
similar distance analysis between amino acid groups K334-
F335 and D695-Q699 yielded a distance of 13.6 Å (23). Our
previous study also revealed that there was a signiﬁcant
difference in the R-helix motif encompassing the region
S528-F538 in factor VaKF and factor VaAA. However, in the
case of factor Va3K, the S528-F538 R-helix and the R321-V331/
K365-T369  -sheet appear to be unaffected by the mutations.
Although one would expect the immediate milieu of factor
Va3K to be similar to factor VaKF in the region encompassing
amino acids 334 and 335, it appears that because of the
second set of mutations (in region 695-698) factor Va3K
adopts a different conformation. Thus, although the second-
ary structures described in factor Va3K were not affected
structurally, the general conformation of the molecule in that
region changed signiﬁcantly. These data suggest a rearrange-
FIGURE 5: Structural analysis of factor Va heavy chain. The ﬁgure
illustrates the ﬁnal snapshot (3 ns) of factor Va3K with the mutated
amino acid residues K334 and F335 depicted as blue sticks and amino
acid residues K695,F 696,K 697, and F698 as red sticks. The region
encompassing amino acid residues S528-F538 (R-helix) is represented
as a red cartoon. The antiparalel  -sheet structures of amino acid
residues R321-V331 and K365-T369 are colored yellow. Amino acid
region R400-H420 is shown as cyan ribbons. Amino acid residues
H362 and F538 are shown as green sticks. S412 is shown as cyan
sticks. N534 and K364 are shown as lime sticks. E323 is shown as
orange sticks.
12840 Biochemistry, Vol. 47, No. 48, 2008 Barhoover et al.ment of amino acids belonging to both sites following amino
acid substitution. These rearrangements are detrimental to
cofactor activity as demonstrated by our kinetic experiments
and the thermodynamic data. This, in turn, can be attributed
to the impaired interaction between factor Va and factor Xa
(illustrated by the decreased afﬁnity of the mutant molecules
for factor Xa).
Earlier data have demonstrated that meizothrombin has
increased catalytic efﬁciency toward chromogenic and ﬂuo-
rogenic substrates usually employed to assess R-thrombin
formation (3, 35-37) and that factor Va interacts with the
substrate,prothrombin,viatheheavychainofthemolecule(8,10).
A synthetic peptide, representing amino acid residues
697-709 from the COOH terminus of the heavy chain of
factor Va, was found to interact directly with R-thrombin-
agarose, indicating that these amino acid residues of the
cofactor provide a binding site for R-thrombin and/or
prothrombin (18, 19). Keeping all these ﬁndings in mind,
we have recently established that the acidic COOH-terminal
portion of factor Va heavy chain controls the rate of
meizothrombin cleavage at Arg271 by factor Xa within
prothrombinase, providing a productive interactive site of
the cofactor with prothrombin, and thus contributes signiﬁ-
cantly to the enhanced function of prothrombinase (20, 21).
In contrast, Toso and Camire using recombinant proteins
have reported that the acidic COOH-terminal region of factor
Va heavy chain does not contribute to the increased catalytic
activity of prothrombinase with respect to prothrombin
activation (38). This conclusion was surprising and at odds
with the data provided in their work since they show that
prothrombinases assembled with recombinant cofactor mol-
ecules with deletions at the carboxy-terminal end of factor
Va heavy chain, factor Va692 (missing amino acid residues
693-709) and factor Va678 (missing amino acid residues
679-709), display kcat values that are 1.3- and 1.5-fold
increased, respectively, compared to the catalytic efﬁciency
of prothrombinase assembled with recombinant factor VaWt
(38). Experiments provided here also demonstrate that
prothrombinases assembled with recombinant factor VaKFKF
and factor Va4A display 1.2- and 1.4-fold increased kcat values,
respectively, compared to the catalytic efﬁciency of pro-
thrombinase assembled with recombinant factor VaWt because
of sustained meizothrombin formation during prothrombin
activation. These results are in complete agreement with
earlier data (18, 39-41) and our recent ﬁndings (21), and
the combined ﬁndings clearly demonstrate that the sequence
695DYDY698 controls meizothrombin concentration by con-
trolling the rate of cleavage at Arg271 during prothrombin
activation by prothrombinase.
The bulk of the data published by our laboratory provide
strong evidence pointing to the fact that the COOH-terminal
acidic region of factor Va heavy chain and in particular
amino acid sequence DYDY is crucial for efﬁcient R-throm-
bin generation at the place of vascular injury. Bearing in
mind the poor ﬁbrinogen clotting properties of meizothrom-
bin, we can hypothesize that following vascular injury,
individuals with a factor Va molecule lacking the COOH-
terminal region of the heavy chain will produce more
meizothrombin, rather than R-thrombin, at the place of
vascular injury, resulting in mild bleeding tendencies. This
hypothetical situation is veriﬁed by clinical data obtained
from patients that are homozygous for an amino acid
substitution in the prothrombin gene at Arg271 (42-46). All
these patients that have a prothrombin molecule that is unable
to be cleaved at Arg271 circulating in their plasma were
identiﬁed because of their hemorrhagic syndrome clinically
resembling mild hemophilia. Thus, while meizothrombin can
competently substitute for most of R-thrombin’s procoagulant
and anticoagulant functions locally at the place of vascular
injury in the presence of an adequate membrane surface
(33, 47-52), the molecule still lacks the ultimate procoagu-
lant function (i.e., efﬁcient ﬁbrin formation). All these
observations together with the fact that prothrombin can be
activated through two distinct pathways that differ in terms
of rate constants and intermediates may allow for the design
of novel anticoagulant molecules with the potential to act
as a control switch and able to modulate speciﬁc events
during R-thrombin (and meizothrombin) formation according
to a precise need. DYDYQ may be the prototype for such a
class of anticoagulants, and we have recently reported that
DYDYQ inhibits prothrombin activation on the surface of
endothelial cells (28), attesting to its physiological potency.
Thus, if the requirement for anticoagulant therapy is to slow
generation of R-thrombin activity without eliminating its
production, thus generating a mild hemophilia phenotype in
patients with thrombotic tendencies, a low concentration of
DYDYQ will be enough to alleviate R-thrombin formation
through the meizothrombin pathway (20). In contrast, if
complete arrest of R-thrombin formation is required, higher
concentrations of DYDYQ will completely eliminate R-throm-
bin generation through the prethrombin 2 pathway as well.
In conclusion, pentapeptide DYDYQ provides an ideal
backbone for exosite-directed anticoagulant molecules that
could attenuate or fully suppress R-thrombin formation in
individuals with thrombotic tendencies.
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